Voyager Therapeutics (NASDAQ:VYGR) Now Covered by Analysts at Citigroup

Investment analysts at Citigroup began coverage on shares of Voyager Therapeutics (NASDAQ:VYGR) in a report released on Monday, MarketBeat reports. The brokerage set a “buy” rating and a $12.00 price target on the stock. Citigroup’s price target would indicate a potential upside of 82.65% from the stock’s previous close.

Several other equities research analysts also recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a report on Thursday, November 14th. Leerink Partners started coverage on shares of Voyager Therapeutics in a report on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 price objective for the company. Wedbush assumed coverage on shares of Voyager Therapeutics in a research note on Friday, November 29th. They set an “outperform” rating and a $11.00 price objective on the stock. Canaccord Genuity Group restated a “buy” rating and issued a $14.00 target price on shares of Voyager Therapeutics in a research report on Thursday, November 14th. Finally, Leerink Partnrs upgraded Voyager Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 16th. Nine investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $17.00.

Voyager Therapeutics Trading Down 5.2 %

VYGR opened at $6.57 on Monday. The business’s 50 day moving average is $6.54 and its 200-day moving average is $7.26. The stock has a market cap of $358.92 million, a PE ratio of 9.25 and a beta of 0.90. Voyager Therapeutics has a twelve month low of $5.19 and a twelve month high of $11.72.

Voyager Therapeutics (NASDAQ:VYGR) last announced its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.29. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The firm had revenue of $24.63 million for the quarter, compared to the consensus estimate of $12.63 million. During the same quarter in the previous year, the business earned ($0.59) EPS. As a group, analysts forecast that Voyager Therapeutics will post -0.89 EPS for the current year.

Insider Activity

In other Voyager Therapeutics news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the business’s stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total transaction of $34,914.18. Following the sale, the insider now owns 86,001 shares in the company, valued at approximately $500,525.82. The trade was a 6.52 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 4.53% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in VYGR. China Universal Asset Management Co. Ltd. increased its holdings in shares of Voyager Therapeutics by 64.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock valued at $61,000 after purchasing an additional 4,098 shares during the period. Intech Investment Management LLC bought a new stake in shares of Voyager Therapeutics in the third quarter valued at about $74,000. SG Americas Securities LLC acquired a new position in shares of Voyager Therapeutics in the second quarter valued at $85,000. Victory Capital Management Inc. increased its stake in Voyager Therapeutics by 14.5% in the second quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock valued at $102,000 after acquiring an additional 1,630 shares during the period. Finally, Hsbc Holdings PLC bought a new stake in Voyager Therapeutics in the second quarter valued at $128,000. 48.03% of the stock is currently owned by institutional investors and hedge funds.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.